Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01981252 · ClinicalTrials.gov registry record · NA
Peri-orbital and Peri-oral Wrinkle Reduction Trial
A NA study, sponsored by Ulthera.
- Terminated
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT01981252: Clinical Trial NA study, sponsored by Ulthera.
NCT01981252 is a NA study that was terminated before completion, run by Ulthera. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01981252, a NA study, was terminated before completion, sponsored by Ulthera.
- TERMINATED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
This is prospective, multi-center, single-blinded, non-randomized clinical trial. Enrolled subjects will receive two Ulthera® treatments on the peri-orbital and peri-oral regions, each treatment provided 30 days apart. Follow-up visits will occur at 90 and 180 days following treatment. Study images will be obtained pre-treatment, immediately post-treatment, and at each follow-up visit.
Primary Outcome
Assessment of improvement, in a blinded fashion, using the Fitzpatrick Wrinkle Scale at 90 days post-treatment #2.
Interventions
- DEVICE Ulthera® System Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-08 |
| Phase | NA |
Why NCT01981252 stopped before completion
NCT01981252 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Ulthera® System Treatment is the first listed.
NCT01981252 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01981252 about?
NCT01981252 is a clinical study titled "Peri-orbital and Peri-oral Wrinkle Reduction Trial". This is prospective, multi-center, single-blinded, non-randomized clinical trial. Enrolled subjects will receive two Ulthera® treatments on the peri-orbital and peri-oral regions, each treatment provided 30 days apart. Follow-up visits will occur at 90 and 180 days following treatment. Study images ...
What is the current status of trial NCT01981252?
This trial is currently terminated. It is a NA study. The enrollment target is 90 participants. The study started on 2013-10. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01981252?
The interventions under investigation include: Ulthera® System Treatment (DEVICE).
Who is sponsoring clinical trial NCT01981252?
This trial is sponsored by Ulthera, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01981252's enrollment target sits among peer trials
90 941st of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia